IBRX logo

ImmunityBio

IBRX · What the business does, what can go wrong, and how options sellers approach it

What it does

ImmunityBio is a biotechnology company that develops immunotherapies. These are treatments meant to help a patient's own immune system recognize and attack cancer, and in some programs, infectious diseases.

Its lead product is ANKTIVA, a protein designed to stimulate immune cells called natural killer cells and T cells. The company also works on vaccines built on adenovirus vectors, natural killer cell therapies and other immune-modulating drugs. It groups much of this work under the name Cancer BioShield.

How it makes money

The main source of revenue is selling ANKTIVA, which is approved in the United States for certain bladder cancers. Revenue depends on how many patients are treated, how doctors prescribe it, and how insurers reimburse it.

Other possible sources include approvals in new regions, new uses for existing drugs, and partnerships or licensing. The company has historically spent more on research and development than it has earned, so funding matters.

Why investors own it

  • Exposure to cancer immunotherapy, a field with large unmet medical need.
  • A commercial product plus a broad pipeline, which offers more than one possible source of growth.
  • The chance that new indications or combinations could widen the market for its drugs.

What can go wrong

  • Clinical trials can fail or be delayed, and regulators can reject or limit approvals.
  • Sales of an approved drug may grow more slowly than expected, especially if competing treatments prove more effective or easier to use.
  • Cash needs may lead to share issuance or debt, which can dilute existing shareholders.
  • Manufacturing, reimbursement and regulatory disputes can disrupt operations.

What to watch

  • ANKTIVA sales trends, prescriber uptake and reimbursement decisions
  • Regulatory decisions and label expansions in the US and abroad
  • Clinical trial readouts and enrollment updates
  • Cash position, spending and any financing announcements
  • Manufacturing capacity and supply updates

Options income angle

Options on IBRX are generally available, though liquidity and bid-ask spreads can vary by strike and expiration.

Implied volatility is usually driven by clinical data, regulatory decisions, financing news, sales updates and broader sentiment toward biotech stocks. It often rises ahead of these events and can fall sharply afterward.

One caution: a binary event such as a trial result or regulatory ruling can move the stock far more than the premium collected from selling options.

Follow IBRX in Kortex

The Kortex app shows IBRX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.